Home | Product Development | Corporate Information | Picture Gallery | Careers | Contact Us | Employee Login
 
 
 
  Our Products
  All Products
List of Generics
  Therapeutic Classes
 
CORE BRANDS
 
PRODUCT
Poze G
 
Generic:
Glimepiride
 
Therapeutic Class:
Antidiabetic
 
Composition:

Poze G Tab 30 mg/ 2 mg
Each tablet contains 30 mg pioglitazone hydrochloride with 2 mg glimepiride.

Poze G Tab 30 mg/ 4 mg
Each tablet contains 30 mg pioglitazone hydrochloride with 4 mg glimepiride.

 
Description:

Poze G tablets contain two oral antihyperglycemic agents used in the management of type 2 diabetes: pioglitazone hydrochloride and glimepiride.

Pioglitazone hydrochloride acts primarily by decreasing insulin resistance. It improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis. It reduces circulating insulin levels and improves glycemic control.

Glimepiride is an oral glucose-lowering drug of the sulphonylurea class, which acts by increasing the release of insulin from the pancreatic beta cells.

 
Indications:
Poze G is indicated as an adjunct to diet and exercise as a once-daily combination therapy to improve glycemic control in patients with type 2 diabetes who are already treated with a combination of pioglitazone and a sulfonylurea or whose diabetes is not adequately controlled with a sulfonylurea alone, or for those patients who have initially responded to pioglitazone alone and require additional glycemic control.
 
Dosage:

General
The use of antihyperglycemic therapy in the management of type 2 diabetes should be individualized on the basis of effectiveness and tolerability.

Dosage Recommendations
Selecting the starting dose of Poze G should be based on the patient’s current regimen of pioglitazone and/or sulfonylurea. It is recommended that a single dose of Poze G be administered once daily with the first main mea.
Starting dose for patients currently on glimepiride monotherapy
Based on the usual starting dose of pioglitazone (15 mg or 30 mg daily), Poze G may be initiated at 30 mg/2 mg or 30 mg/4 mg tablet strengths once daily, and adjusted after assessing adequacy of therapeutic response.
Starting dose for patients currently on pioglitazone monotherapy
Based on the usual starting doses of glimepiride (1 mg or 2 mg once daily), and pioglitazone 15 mg or 30 mg, Poze G may be initiated at 30 mg/2 mg once daily, and adjusted after assessing adequacy of therapeutic response.
Starting dose for patients switching from combination therapy of pioglitazone plus glimepiride as separate tablets
Poze G may be initiated with 30 mg/2 mg or 30 mg/4 mg tablet strengths based on the dose of pioglitazone and glimepiride already being taken. Patients who are not controlled with 15 mg of pioglitazone in combination with glimepiride should be carefully monitored when switched to Poze G.

Maximum Recommended Dose
Poze G tablets are available as a 30 mg pioglitazone plus 2 mg glimepiride or a 30 mg pioglitazone plus 4 mg glimepiride formulation for oral administration. The maximum recommended daily dose for pioglitazone is 45 mg and the maximum recommended daily dose for glimepiride is 8 mg. Poze G should therefore not be given more than once daily at any of the tablet strengths. 

 
Presentations:
Poze G 30 mg/ 2 mg is available in 14’s
Poze G 30 mg/ 4 mg is available in 14’s